[go: up one dir, main page]

AR076601A1 - Pirimidinas como agentes terapeuticos - Google Patents

Pirimidinas como agentes terapeuticos

Info

Publication number
AR076601A1
AR076601A1 ARP100101785A ARP100101785A AR076601A1 AR 076601 A1 AR076601 A1 AR 076601A1 AR P100101785 A ARP100101785 A AR P100101785A AR P100101785 A ARP100101785 A AR P100101785A AR 076601 A1 AR076601 A1 AR 076601A1
Authority
AR
Argentina
Prior art keywords
aromatic
nhc
unsubstituted
alkyl
independently
Prior art date
Application number
ARP100101785A
Other languages
English (en)
Original Assignee
Chlorion Pharma Inc
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chlorion Pharma Inc, Univ Laval filed Critical Chlorion Pharma Inc
Publication of AR076601A1 publication Critical patent/AR076601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de cualquiera de las Formulas ((1a-2)-(1a-21)), incluyendo otros tautomeros, estereoisomeros, estereoisomeros E/Z, profármacos, sales farmacéuticamente aceptables, y también caracteriza composiciones, métodos para tratar o prevenir dolor (por ej., dolor neuropático), inflamacion, o epilepsia y como anticonvulsivos. Reivindicacion 1: Un compuesto que tiene la siguiente estructura (1a) y sus tautomeros (1b), incluyendo otros tautomeros, estereoisomeros, estereoisomeros E/Z, profármacos y sus sales farmacéuticamente aceptables, donde Q1 es -O-, -S-, -SO-, -SO2-, -CH2-, -CH2CH2-, -CH=CH-, -OCH2-, -SCH2-, -SOCH2-, o -SO2CH2-; V es O, S, NH, o NZ, o amino ácido ligado a N-terminal, halogeno, o H cuando R1 está ausente; R1 está ausente, -H, alquilo C1-8, alquenillo C2-8, alquinilo C2-8, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, -(CH2)nOZ, -C(O)Z, -C(O)OZ, -C(O)NHZ, -C(O)N(Z)2, -(CR1AR1B)r2OPO(OZ)2, -(CR2AR2B)r3PO(OZ)2, o aminoácido ligado a C-terminal; cada R1A, R1B, R2A y R2B es, de manera independiente, H o alquilo C1-5; cada Z es, de manera independiente, -H, alquilo C1-8, alqcicloalquilo C4-12, alqheterociclilo C3-9, donde el heterociclilo es de 3 a 9 miembros, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, heterociclilo 3 a 9 miembros aromático o no aromático, alquenilo C2-8, o alquinilo C2-8, o dos Z, junto con el átomo(s) al cual cada uno está adherido, se juntan para formar un heterociclo de 3 a 7 miembros aromático o no aromático; cada n es 1 o 2; cada r2 es un numero entero entre 1-3; cada r3 es un numero entero entre 0-2; R2 y R3 son cada uno, de manera independiente, -H, -D, -OH, -halogeno, -CN, -NO2, -SH, -CF3, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, heterociclilo de 3 a 9 miembros aromático o no aromático, -OZ, -N(Z)2, -C(NH)N(Z)2, -O(CH2)nOZ, -C(O)Z, -OC(O)Z, -OC(O)OZ, -OC(O)N(Z)2, -C(O)N(Z)2, -C(O)OZ, -SZ, -SOZ, -S(O)2Z, -NHC(O)Z, -NHS(O)2Z, -NHC(NH)N(Z)2, -NZC(NH)N(Z)2, - NHC(NCN)N(Z)2, -NZC(NCN)N(Z)2, o -PO(OZ)2, o R2 y R3, junto con el átomo al cual cada uno está adherido, se juntan para formar un carbociclo o heterociclo de 5 o 6 miembros aromático o no aromático; A1 y A2 son cada uno, de manera independiente, -H, -D, -halogeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, -arilo C6-12, o arilalquilo C7-14; A3 es un anillo heterocíclico aromático seleccionado entre el grupo integrado por los fragmentos A-1 a A-4; Q2, Q5 y Q6 son cada uno, de manera independiente, N, N+-O-, o C; Q3 y Q4 son cada uno, de manera independiente, N, N+-O-, C, O, o S, donde solamente uno de Q3 y Q4 puede ser O u S; donde Q2, Q3, Q4, Q5 y Q6 simultáneamente son C solo si R4 y R5, R5 y R6, R6 y R7, o R7 y R8, junto con los átomos al cual cada uno está adherido, se unen para formar un heterociclilo de 5 a 6 miembros aromático o no aromático; y R4, R5, R6, R7 y R8 son cada uno, de manera independiente, ausente, -H, -D, -OH, -O, -halogeno, -CN, -NO2, -SH, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, heterociclilo de 3 a 9 miembros aromático o no aromático, -OZ, -N(Z)2, -C(NH)N(Z)2, -O(CH2)nOZ, -C(O)Z, -OC(O)Z, -OC(O)OZ, -OC(O)N(Z)2, -C(O)N(Z)2, -C(O)OZ, -SZ, -SOZ, -S(O)2Z, -NHC(O)Z, -NHS(O)2Z, -NHC(NH)N(Z)2, -NZC(NH)N(Z)2, -NHC(NCN)N(Z)2, -NZC(NCN)N(Z)2, -PO(OZ)2, o R4 y R5, o R5 y R6, o R6 y R7, o R7 y R8, junto con los átomos al cual cada uno está adherido, se unen para formar un carbociclo o heterociclo de 5 a 6 miembros aromático o no aromático siempre y cuando el sistema anular resultante no esté sustituido o bencimidazol no sustituido, no sustituido benzotiazol, imidazo[1,2-a]piridina no sustituido, 5- o 6- cloro-imidazo[1,2-a]piridina, indol cuando R2 es C(O)OCH2CH3, quinolina no sustituido, quinolina 8-sustituida, quinoxalina no sustituido, 2- o 4-cloro-quinolina, 2-cloro-7-metil-quinolina o 2-piperidin-1-il-quinolina cuando R3 es NH2, o 4-hidroxi-1,3-quinazolina, donde cuando A3 es piridina-2-il no sustituido y A1, y A2 son cada uno -H, R3 no es -H, -OH, -NH2, -CF3, alquilo C1-3, fenilo, difluorobencil, -NHC(O)furan, -NHC(O)CH3, o -NHC(O)CH2CH3; donde cuando A3 es piridina-4-il no sustituido y A1 y A2 son cada uno -H, R3 no es -H, -OH, -NH2, -CH3, -CH2CH2CH3, o difluorobencil; donde cuando A3 es no sustituido, 6-cloro, o 2,6-dicloro piridina-3-il y A1 y A2 son cada uno -H, R3 no es -H, -OH, -NH2, -CF3, alquilo C1-3, fenilo, -C(O)OCH2CH3, o -NHC(O)CH3; donde cuando A3 es pirazol-1-il sustituido o no sustituido, R3 no es -OH; y donde A3 no es 4-NO2-imidazol-2-il.
ARP100101785A 2009-05-21 2010-05-21 Pirimidinas como agentes terapeuticos AR076601A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18025309P 2009-05-21 2009-05-21
US28500309P 2009-12-09 2009-12-09
US28962809P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
AR076601A1 true AR076601A1 (es) 2011-06-22

Family

ID=43124965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101785A AR076601A1 (es) 2009-05-21 2010-05-21 Pirimidinas como agentes terapeuticos

Country Status (6)

Country Link
US (2) US9040538B2 (es)
EP (1) EP2432776B1 (es)
AR (1) AR076601A1 (es)
CA (1) CA2762680C (es)
TW (1) TW201100411A (es)
WO (1) WO2010132999A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
EP2523661B1 (en) 2010-01-15 2017-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitors for the treatment of autism
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
CN102070553B (zh) * 2010-12-17 2013-08-07 西安瑞联近代电子材料有限责任公司 一种噻唑-4-甲醛的合成方法
EP2707373A1 (de) 2011-05-10 2014-03-19 Bayer Intellectual Property GmbH Bicyclische (thio)carbonylamidine
EP2729476B1 (de) 2011-07-06 2017-08-23 Bayer Intellectual Property GmbH Heteroaryl-substituierte pyrazolopyridine und ihre verwendung als stimulatoren der löslichen guanylatcyclase
DE102012200354A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
CN103857657B (zh) 2011-08-18 2016-04-20 日本新药株式会社 杂环衍生物及医药
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
EP2822951B1 (de) 2012-03-06 2017-07-26 Bayer Intellectual Property GmbH Substituierte azabicyclen und ihre verwendung
EP2732815A1 (en) 2012-11-16 2014-05-21 Neurochlore Modulators of intracellular chloride concentration for treating fragile X syndrome
WO2014139983A1 (en) 2013-03-13 2014-09-18 H. Lundbeck A/S [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors
KR20150142014A (ko) 2013-04-12 2015-12-21 바이엘 크롭사이언스 악티엔게젤샤프트 신규 트리아졸 유도체
WO2014167010A1 (en) 2013-04-12 2014-10-16 Bayer Cropscience Ag Novel triazole derivatives
US9550752B2 (en) 2013-04-12 2017-01-24 Bayer Cropscience Aktiengesellschaft Triazolinthione derivatives
MX360455B (es) 2013-05-14 2018-11-01 Active Biotech Ab Derivados de n-(heteroaril)-sulfonamida utiles como inhibidores de s100.
MX2016000258A (es) 2013-07-10 2016-04-28 Bayer Pharma AG Bencil-1h-pirazolo[3,4-b]piridinas y su uso.
CN104693114B (zh) * 2013-12-10 2019-08-16 四川海思科制药有限公司 一种贝曲西班的改进的制备方法
RU2537848C1 (ru) * 2013-12-10 2015-01-10 Федеральное государственное казенное учреждение "33 Центральный научно-исследовательский испытательный институт Министерства обороны Российской Федерации" Способ получения 2-хлор-5-гидроксиметилпиридина
US9510593B2 (en) * 2014-01-17 2016-12-06 Valent Biosciences Corporation S-benzylthiouracil compounds and methods of enhancing plant root growth
US10525024B2 (en) 2014-08-15 2020-01-07 The Johns Hopkins University Methods for rescuing phenobarbital-resistance of seizures by ANA-12 or ANA-12 in combination with CLP290
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
CN104478795A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种2-氯烟醛的制备方法
WO2016156294A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Triazol derivatives as fungicides
PE20180175A1 (es) 2015-04-02 2018-01-22 Bayer Cropscience Ag Nuevos derivados de imidazolilmetilo 5-sustituidos
UY36949A (es) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-dihidroxi-nicotinamidas como agonistas de apj
CA3008630A1 (en) 2015-12-16 2017-06-22 Bristol-Myers Squibb Company Heteroarylhydroxypyrimidinones as agonists of the apj receptor
AU2017238504B2 (en) 2016-03-24 2021-05-27 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
KR20190026902A (ko) 2016-07-14 2019-03-13 화이자 인코포레이티드 바닌-1 효소의 억제제로서의 신규 피리미딘 카르복스아미드
CN109843065A (zh) 2016-09-13 2019-06-04 拜耳作物科学股份公司 包含5-取代的咪唑衍生物的活性化合物结合物
WO2018060073A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazole derivatives
BR112019006450A2 (pt) 2016-09-29 2019-06-25 Bayer Cropscience Ag novos derivados de imidazolilmetila substituídos na posição 5
US20200045972A1 (en) 2016-09-29 2020-02-13 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
CN106946772B (zh) * 2016-11-02 2019-08-06 河南省商业科学研究所有限责任公司 一种2,2’-联吡啶-4,4’-甲酸甲酯的合成方法
US12156523B2 (en) * 2017-03-17 2024-12-03 Mmag Co., Ltd. Plant disease control agent
ES2938335T3 (es) 2017-03-24 2023-04-10 St Pharm Co Ltd Nuevo derivado de pirrolopiridina, método para producir el mismo y uso del mismo
US11827616B2 (en) 2017-05-04 2023-11-28 Discovery Purchaser Corporation Heterocyclic compounds as pesticides
CN107286083A (zh) * 2017-06-16 2017-10-24 康化（上海）新药研发有限公司 一种2‑氯‑6‑溴‑3‑吡啶甲醛的合成方法
JP2021502402A (ja) 2017-11-13 2021-01-28 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ テトラゾリルプロピル誘導体および殺真菌剤としてのそれらの使用
US10300100B1 (en) 2018-09-27 2019-05-28 King Saud University Extract of Vicia faba beans
BR112022005463A2 (pt) 2019-09-25 2022-06-14 Pfizer Moduladores poli-heterocíclicos de sting (estimulador de genes de interferon)
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN118748993A (zh) 2021-12-28 2024-10-08 日本新药株式会社 吲唑化合物和药物
WO2023196614A1 (en) * 2022-04-08 2023-10-12 Axonis Therapeutics, Inc. Methods and compounds for treating neurological disorders
AU2024243715A1 (en) * 2023-04-05 2025-10-09 Axonis Therapeutics, Inc. Kcc2 potentiators and uses thereof
WO2024233885A2 (en) * 2023-05-11 2024-11-14 Axonis Therapeutics, Inc. Kcc2 potentiators and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3369514D1 (en) 1983-05-05 1987-03-05 Heumann Ludwig & Co Gmbh Pyrimidinethioalkyl pyridine derivatives, process for their preparation and medicines containing these compounds
HU203736B (en) 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
US5472967A (en) * 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
JPH06206805A (ja) 1992-02-17 1994-07-26 Hisamitsu Pharmaceut Co Inc チロシナーゼ阻害剤及びそれを用いた皮膚外用剤
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
EP0728130A1 (en) * 1993-11-12 1996-08-28 PHARMACIA & UPJOHN COMPANY Pyrimidine-thioalkyl and alkylether compounds
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
UA56992C2 (uk) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
JP2001506666A (ja) 1996-12-20 2001-05-22 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング イミダゾピリダジン
AR023071A1 (es) 1998-12-23 2002-09-04 Syngenta Participations Ag Compuestos de piridincetona, compuestos intermediarios, composicion herbicida e inhibidora del crecimiento de plantas, metodo para controlar la vegetacion indeseada, metodo para inhibir el crecimiento de las plantas, y uso de la composicion para controlar el crecimiento indeseado de plantas.
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GT200100103A (es) 2000-06-09 2002-02-21 Nuevos herbicidas
CA2443697A1 (en) 2001-04-13 2002-10-24 Pier F. Cirillo 1,4-disubstituted benzo-fused compounds
EP1392661A1 (en) 2001-05-16 2004-03-03 Boehringer Ingelheim Pharmaceuticals Inc. Diarylurea derivatives useful as anti-inflammatory agents
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
CA2446193C (en) 2001-06-05 2011-11-01 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
JP2003206230A (ja) 2002-01-10 2003-07-22 Yamanouchi Pharmaceut Co Ltd シアノヘテロ環誘導体又はその塩
WO2004014870A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
SI1601653T1 (sl) 2003-03-07 2009-06-30 Syngenta Participations Ag Postopek za pripravo substituiranih estrov nikotinske kisline
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
JP4534452B2 (ja) * 2003-09-04 2010-09-01 株式会社クレハ ３−メチルイソチアゾール−５−メタノール誘導体、その製造法および農園芸用病害防除剤
JP2007505050A (ja) * 2003-09-12 2007-03-08 アルピダ エー／エス ペプチドデホルミラーゼ阻害剤としてのイソキサゾール類
PT1809624E (pt) 2004-08-28 2014-01-14 Astrazeneca Ab Derivados de pirimidina sulfonamida como moduladores do recetor de quimiocina
WO2006031852A1 (en) * 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2008516938A (ja) * 2004-10-15 2008-05-22 アストラゼネカ アクチボラグ 置換アデニンとその使用
CA2586334A1 (en) 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
CN101184493A (zh) * 2005-03-04 2008-05-21 阿尔斯根公司 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
WO2006133353A2 (en) 2005-06-08 2006-12-14 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
CN101522687A (zh) * 2006-01-30 2009-09-02 阿雷生物药品公司 用于癌症治疗的杂二环噻吩化合物
RU2522430C2 (ru) * 2008-01-22 2014-07-10 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи 5-фторпиримидиновые производные в качестве фунгицидов
WO2010027097A1 (en) 2008-09-04 2010-03-11 Mitsubishi Tanabe Pharma Corporation Tri-substituted pyrimidine compounds and their use as pde10 inhibitors
EP2342191B1 (en) * 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos

Also Published As

Publication number Publication date
US9315521B2 (en) 2016-04-19
EP2432776A4 (en) 2012-10-24
US20100298336A1 (en) 2010-11-25
CA2762680A1 (en) 2010-11-25
WO2010132999A1 (en) 2010-11-25
EP2432776A1 (en) 2012-03-28
US20150225423A1 (en) 2015-08-13
CA2762680C (en) 2018-04-17
TW201100411A (en) 2011-01-01
EP2432776B1 (en) 2019-09-11
WO2010132999A8 (en) 2011-06-30
US9040538B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
AR076601A1 (es) Pirimidinas como agentes terapeuticos
ES2975183T3 (es) Inhibidores de ENPP1 y su uso para el tratamiento del cáncer
KR102237707B1 (ko) 퀴놀론계를 대체하는 유도체 또는 그의 약학적으로 수용가능한 염 또는 입체이성체 및 이들의 의약용 조성물과 응용
JP2025098199A (ja) 免疫応答をモジュレートするｅｎｐｐ１阻害剤および方法
Bregman et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors
ES2974334T3 (es) Inhibidores heterocíclicos de ATR cinasa
AU760020B2 (en) Novel angiogenesis inhibitors
AR050788A1 (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
JP5656634B2 (ja) タンパク質チロシンキナーゼ活性の阻害剤
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
JP7341156B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
CA2392971C (en) 2,4-diaminopyrimidine compounds useful as immunosuppressants
ES2734735T3 (es) Derivados de 4-oxo-3,4-dihidro-1,2,3,-benzotriazina como moduladores de GPR139
AR053232A1 (es) Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico.
AR059246A1 (es) Compuestos heterobiciclicos de tiofeno y metodos de uso
PE20090960A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
PE20030922A1 (es) Derivados de piridina y quinolina
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
RU2006139258A (ru) Бензотриазиновые ингибиторы киназ
EA024194B1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
ES2564010T3 (es) Composición farmacéutica para tratar o prevenir el glaucoma
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
RU2011108024A (ru) 3-азабицикло(3.1.0) гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов

Legal Events

Date Code Title Description
FB Suspension of granting procedure